Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.

Biochemical pharmacology - 1 Sept 2022

Zhang Xiaonan, Akcan Ece, Correia Mario, Rameika Natallia, Kundu Snehangshu, Stoimenov Ivaylo, Rendo Veronica, Eriksson Anna U, Haraldsson Martin, Globisch Daniel, Sjöblom Tobias

Abstract excerpt

Loss of heterozygosity (LOH) is a hallmark feature of cancer genomes that reduces allelic variation, thereby creating tumor specific vulnerabilities which could be exploited for therapeutic purposes. We previously reported that loss of drug metabolic arylamine N-acetyltransferase 2 (NAT2) activity following LOH at 8p22 could be targeted for collateral lethality anticancer therapy in colorectal cancer (CRC). Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetyltransferases
Share to Adenosine Triphosphatases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles

Share to Antineoplastic Agents

Share to Arylamine N-Acetyltransferase

Share to Colorectal Neoplasms

Source

Identifiers

PMID: 35872325
DOI: 10.1016/j.bcp.2022.115184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.PMID 35872325Read ↗

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.Semantic proximity Read ↗

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.Semantic proximity Read ↗

NAD+ biosynthesis as a collateral lethality target for precision oncologySemantic proximity Read ↗

Prediction of individualized therapeutic vulnerabilities in cancer from genomic profilesSemantic proximity Read ↗

Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparibSemantic proximity Read ↗

The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancersSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

High-Throughput Targeted Drug Screening for NF1-associated High-Grade Gliomas with ATRX DeficiencySemantic proximity Read ↗

Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination TherapySemantic proximity Read ↗

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.Semantic proximity Read ↗

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities.Semantic proximity Read ↗

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.